Product Details of 41575-94-4. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. Author is Rolfo, Christian; Drilon, Alexander; Hong, David; McCoach, Caroline; Dowlati, Afshin; Lin, Jessica J.; Russo, Alessandro; Schram, Alison M.; Liu, Stephen V.; Nieva, Jorge J.; Nguyen, Timmy; Eshaghian, Shahrooz; Morse, Michael; Gettinger, Scott; Mobayed, Mohammad; Goldberg, Sarah; Araujo-Mino, Emilio; Vidula, Neelima; Bardia, Aditya; Subramanian, Janakiraman; Sashital, Deepa; Stinchcombe, Thomas; Kiedrowski, Lesli; Price, Kristin; Gandara, David R..
Activating fusions of the NTRK1, NTRK2 and NTRK3 genes are drivers of carcinogenesis and proliferation across a broad range of tumor types in both adult and paediatric patients. Recently, the FDA granted tumor-agnostic approvals of TRK inhibitors, larotrectinib and entrectinib, based on significant and durable responses in multiple primary tumor types. Unfortunately, testing rates in clin. practice remain quite low. Adding plasma next-generation sequencing of circulating tumor DNA (ctDNA) to tissue-based testing increases the detection rate of oncogenic drivers and demonstrates high concordance with tissue genotyping. However, the clin. potential of ctDNA anal. to identify NTRK fusion-pos. tumors has been largely unexplored. We retrospectively reviewed a ctDNA database in advanced stage solid tumors for NTRK1 fusions. NTRK1 fusion events, with nine unique fusion partners, were identified in 37 patients. Of the cases for which clin. data were available, 44% had tissue testing for NTRK1 fusions; the NTRK1 fusion detected by ctDNA was confirmed in tissue in 88% of cases. Here, we report for the first time that minimally-invasive plasma NGS can detect NTRK fusions with a high pos. predictive value. Plasma ctDNA represents a rapid, non-invasive screening method for this rare genomic target that may improve identification of patients who can benefit from TRK-targeted therapy and potentially identify subsequent on- and off-target resistance mechanisms.
Different reactions of this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Product Details of 41575-94-4 require different conditions, so the reaction conditions are very important.
Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics